MarginsXMarginsX
Home › Markets › Health Care › FHTX

Foghorn Therapeutics Inc. (FHTX)

FHTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.79
-13.53% on the day
Market cap
$107.3M
Micro cap
Revenue · 2025
$30.9M
+36.8% on 2024
Net income · 2025
-$74.3M
-240.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/0001628280-26-016814-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerFHTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001822462
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$30.9M
Net income-$74.3M
Operating income-$86.4M
Net margin-240.3%
Operating margin-279.5%
Revenue growth+36.8%
Cash$80.9M
Total assets$198.1M
P/E (computed)Net income was not positive
P/S (computed)3.5×

Warning signs

Cash runway
11.5 months
$80.3M cash at September 30, 2026
Share count, 1 year
+6.0%
2025-10-31 to 2026-10-30 · +42.0% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$80.3M cash; operating cash flow -$20.9M a quarter.Report 2026-09-30
Shares outstanding59,962,650 (2026-10-30); 56,551,289 a year earlier; 42,217,126 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-01-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$83.5M$58.1M-$18.2M$80.3MNo debt tags$112.1M10-Q 2026-11-09
Q2 2026
2026-06-30
$16.1M-$7.2M-$17.8M$68.1MNo debt tags$36.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$3.3M-$19.9M-$25.3M$87.7MNo debt tags$28.2M10-Q 2026-05-07
Q4 2025
2025-12-31
$9.2M-$21.7M-$22.3M$80.9MNo debt tags$30.9M10-K 2026-03-11
Q3 2025
2025-09-30
$8.2M-$15.8M-$18.9M$89.3MNo debt tags$24.5M10-Q 2026-11-09
Q2 2025
2025-06-30
$7.6M-$17.9M-$21.0M$72.6MNo debt tags$24.2M10-Q 2026-08-06
Q1 2025
2025-03-31
$6.0M-$18.8M-$24.0M$61.0MNo debt tags$23.5M10-Q 2026-05-07
Q4 2024
2024-12-31
$2.9M-$19.5M-$24.5M$55.5MNo debt tags$22.6M10-K 2026-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-01-12
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 356 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+10.7%
1 month+11.9%
3 months-68.1%
Year to date-61.7%
1 year-52.5%
From 52-week high-70.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BGMBGM Group Ltd.$8.01+1.71%$107.0M
ADAGAdagene Inc.$1.60-6.43%$105.7M
NERVMinerva Neurosciences Inc$2.20-4.35%$109.6M
CLLSCellectis S.A.$1.04-11.86%$104.5M
DERMJourney Medical Corporation$3.70-14.55%$104.5M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
OKUROnKure Therapeutics Inc.$2.75+4.56%$111.4M
CATXPerspective Therapeutics Inc.$0.9238-2.05%$111.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier